Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Single-isomer beta-agonists.

D A Handley1

  • 1Sepracor, Inc., Marlborough, Massachusetts 01752, USA.

Pharmacotherapy
|March 20, 2001
PubMed
Summary
This summary is machine-generated.

Single-isomer beta-agonists offer improved asthma management. These medications provide equivalent or superior bronchodilation with fewer side effects compared to traditional racemic bronchodilators.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pursuit of precision pharmaceuticals: divergent effects of beta2 agonist isomers.

Expert opinion on investigational drugs·2005
Same author

Therapeutic advantages of third generation antihistamines.

Expert opinion on investigational drugs·2005
Same author

Levalbuterol hydrochloride.

Expert opinion on investigational drugs·2005
Same author

Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.

The Journal of asthma : official journal of the Association for the Care of Asthma·2000
Same author

New millennium bronchodilators for asthma: single-isomer beta agonists.

Current opinion in pulmonary medicine·1999
Same author

Effects of S-salbutamol on human isolated bronchus.

Pulmonary pharmacology & therapeutics·1998
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Acute asthma management traditionally uses racemic beta-agonists.
  • Racemic mixtures contain both active (eutomer) and inactive/harmful (distomer) isomers.
  • Single-isomer beta-agonists contain only the active eutomer.

Purpose of the Study:

  • To evaluate the efficacy and safety of single-isomer beta-agonists for acute asthma.
  • To compare single-isomer (R)-albuterol (levalbuterol) with racemic albuterol.
  • To establish the rationale for replacing racemic mixtures with single-isomer alternatives.

Main Methods:

  • Review of clinical studies comparing (R)-albuterol with racemic albuterol.
  • Analysis of bronchodilatory effects and beta-mediated side effects.

Related Experiment Videos

  • Assessment of outcomes in severe asthma episodes and emergency department treatment costs.

    • Main Results:

    • Reduced dosages of single-isomer beta-agonists yield equivalent bronchodilation to racemic forms.
    • Single-isomer use is associated with fewer beta-mediated side effects.
    • Higher dosages of single-isomer drugs provide superior bronchodilation in severe asthma.

    Conclusions:

    • Single-isomer beta-agonists represent a new generation of bronchodilators for acute asthma.
    • They offer improved efficacy and safety profiles compared to racemic mixtures.
    • Potential for reduced emergency department treatment costs and enhanced patient outcomes.